[1] CPG. Sec. 420.400 Performance of Tests for Compendial Requirements on Compendial Products [EB/OL].(2010-01-12)[2014-03-26].http://www.fda.gov/iceci/compliancemanuals/compliancepolicyguidancemanual/ucm074370.htm. [2] USPC. Governance [EB/OL]. [2014-03-26].http://www.usp.org/about-usp/leadership/governance. [3] 操洪欣. 药品质量标准[EB/OL].(2011-01-15)[2014-03-26].http:// www.doc88.com/p-714689146410.html. [4] 胡江滨 对接国际标准促进中国医药产业升级-美国药品相关标准内容分析和制定情况介绍 [EB/OL].(2010-12-02)[2014-03-26].http://www.pharmacy.hc360.com/10daquan/secondmenu/ Detail_yjbg5.html. [5] USPC. USP Guideline for Submitting Requests for Revision to USP-NF V5 January 2011[EB/OL].(2011-05-27)[2014-03-26].http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/usp_rfr_general_info_for_all_submissions_v5_jan_2011.pdf. [6] USPC. PENDING MONOGRAPHS GUIDELINE [EB/OL].( 2011-11-01)[2014-03-26].http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/2011-11-01_pending_monographs_guideline_version_2.7.pdf. [7] USPC. USP Guideline on Use of Accelerated Processes for Revisions to the USP-NF Version 3.0 [EB/OL].( 2012-08-31)[2014-03-26].http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/2012-08-31_guideline_on_use_of_accelerated_processes_v3.pdf. [8] USPC.Advancing Health Through Public Standards-USP & FDA's Response to Heparin Crisis: A Timeline of Events [EB/OL].[ 2014-03-26].http://www.usp.org/sites/default/files/usp_pdf/EN/valueOfStandards/heparinTimeline.pdf.